Drug Price Trends for NDC 50458-0611

Average Pharmacy Cost for 50458-0611

Drug Name	NDC	Price/Unit ($)	Unit	Date
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	4018.06372	ML	2026-01-02
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	3923.89036	ML	2025-12-17
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	3923.89036	ML	2025-11-19
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	3923.27510	ML	2025-10-22
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	3923.27510	ML	2025-09-17
INVEGA HAFYERA 1,092 MG/3.5 ML	50458-0611-01	3916.39600	ML	2025-08-20

Best Wholesale Price for NDC 50458-0611

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novartis' Sandimmune (Cyclosporine) Patent Landscape and Market Outlook

Last updated: February 18, 2026

Novartis AG's Sandimmune (cyclosporine) faces a complex patent expiration and market landscape. Key patents protecting the original formulation and manufacturing processes have expired, leading to generic competition. However, secondary patents and ongoing litigation related to formulation improvements and new indications may extend market exclusivity or influence pricing and market share. Current market projections indicate continued price erosion due to generic entrants, with price stability expected to emerge as the market matures.

What is the Original Patent Expiration Timeline for Sandimmune?

The foundational patents for Sandimmune, encompassing its composition of matter and primary manufacturing methods, have long expired. The earliest U.S. patent for cyclosporine itself, U.S. Patent 4,115,709, was filed in 1977 and expired in 1994 [1]. This initial patent provided broad protection for the cyclosporine molecule, the active pharmaceutical ingredient in Sandimmune.

Subsequent patents covered specific formulations and manufacturing processes. For example, patents related to early oral formulations, designed to improve bioavailability and patient compliance, also expired in the early 2000s. The expiration of these core patents opened the door for generic manufacturers to enter the market.

What Are the Key Generic Competitors for Sandimmune?

The generic market for Sandimmune (cyclosporine oral solution and capsules) is highly fragmented, with numerous manufacturers offering bioequivalent products. Major generic players and their approximate market entries include:

• Teva Pharmaceuticals: A consistent participant in the generic market, Teva offers various cyclosporine formulations.
• Sandoz (a Novartis division): While Novartis originally marketed Sandimmune, Sandoz, as a generics arm, also competes in this space.
• Mylan (now Viatris): Viatris, formed by the merger of Mylan and Upjohn, is another significant provider of generic cyclosporine.
• Dr. Reddy's Laboratories: This Indian pharmaceutical company is a notable global supplier of generic cyclosporine.
• Sun Pharmaceutical Industries: Another major Indian generic producer with a substantial portfolio, including cyclosporine.

The entry of these companies has significantly driven down prices compared to the branded Sandimmune. The competition is characterized by a large number of suppliers, leading to intense price pressure.

What Secondary Patents and Litigation Impact Sandimmune's Market?

While the primary patents have expired, Novartis and other innovators have pursued secondary patents to protect improvements and new uses of cyclosporine. These include:

• Formulation Patents: Patents covering specific excipients, stabilizers, or improved delivery systems designed to enhance cyclosporine's solubility, absorption, or palatability. For instance, patents related to microemulsion or nanoemulsion formulations aim to improve bioavailability and reduce variability.
• Indication Patents: Patents protecting the use of cyclosporine for specific therapeutic areas beyond its initial approvals, such as new autoimmune diseases or transplant rejection prophylaxis in novel contexts.
• Manufacturing Process Patents: Improvements in manufacturing efficiency, purity, or cost-effectiveness of cyclosporine production can also be patented.

Litigation often arises from these secondary patents, where generic companies challenge their validity or non-infringement. For example, disputes may occur if a generic manufacturer's formulation is alleged to infringe upon a patented excipient blend or manufacturing step. These legal battles can impact the timing of generic market entry or affect the market share of specific generic products.

How Do Generic Entry and Competition Affect Sandimmune Pricing?

The introduction of generic cyclosporine has led to substantial price reductions. The average selling price (ASP) for cyclosporine has declined by over 80% since the peak of branded market exclusivity. This trend is typical for drugs with multiple generic competitors.

The pricing dynamics can be summarized as follows:

• Initial Price Drop: Upon the first generic entry, prices typically fall by 30-50%.
• Sustained Erosion: With each subsequent generic entrant, prices continue to decrease, often reaching 10-20% of the branded price within a few years.
• Price Stabilization: Eventually, as the market reaches a point of saturation with multiple generic suppliers, price erosion slows, and prices stabilize at a low level.

The ASP of Sandimmune oral solution, for example, has seen a consistent downward trend. Data from sources like GoodRx and industry pricing reports indicate that the average cash price for a 50-count bottle of 100mg/5mL oral solution has fallen from hundreds of dollars to under fifty dollars in recent years. This is a direct consequence of the highly competitive generic marketplace.

What is the Market Size and Growth Projection for Cyclosporine?

The global market for cyclosporine is substantial, driven by its established use in organ transplantation and autoimmune diseases. However, the market growth for the original Sandimmune formulation is stagnant or declining due to genericization.

• Transplant Market: Cyclosporine remains a first-line immunosuppressant for organ transplant recipients, including kidney, liver, and heart transplants. The demand in this segment is relatively stable, driven by the incidence of organ transplantation.
• Autoimmune Disease Market: Cyclosporine is also used to treat conditions such as severe rheumatoid arthritis, psoriasis, and atopic dermatitis. This segment contributes significantly to the overall market.

Market Size and Projections:

The global cyclosporine market was valued at approximately $1.5 billion to $2.0 billion in recent years. Projections indicate a compound annual growth rate (CAGR) of 2-4% for the overall cyclosporine market. This modest growth is attributed to:

• Sustained Demand: Continued need in transplant and autoimmune disease treatment.
• Generic Penetration: The growth is primarily driven by the volume of generic sales, not by price increases.
• Emerging Markets: Expansion of healthcare access in developing countries may contribute to increased volume.
• Competition from Newer Therapies: Newer, more targeted biologics and immunosuppressants are challenging cyclosporine's market share in some autoimmune indications, potentially moderating growth in those segments.

The market is increasingly dominated by generic sales, which account for over 70% of the total cyclosporine volume.

How Do Different Cyclosporine Formulations (e.g., Oral Solution vs. Capsules) Affect Market Dynamics?

Cyclosporine is available in multiple dosage forms, primarily oral capsules and oral solution. These different formulations cater to different patient needs and can have distinct market dynamics:

• Oral Solution: Often preferred for pediatric patients, individuals with swallowing difficulties, or when precise dose titration is required. The oral solution market tends to be more sensitive to pricing due to formulation complexity and the need for specialized manufacturing.
• Capsules: More convenient for adult patients who can swallow pills. The capsule market is highly competitive, with numerous generic manufacturers offering a wide range of strengths.

Market Share and Pricing Differences:

Historically, the branded oral solution had a higher price point and market share due to its specific benefits. However, with generic competition, the price difference between branded and generic solutions has narrowed significantly. The oral solution market is often characterized by:

• Lower Volume, Higher Per-Unit Cost (historically): Due to formulation complexity.
• Brand Loyalty (limited): Physicians may have preferences based on patient experience, but price is a major determinant for payers and patients.

The capsule market is more commoditized, with lower prices and higher competition. The availability of multiple strengths and sizes of generic cyclosporine capsules provides significant choice and drives price competition.

The choice of formulation can also be influenced by patent protection. If a new patent is granted for an improved formulation (e.g., enhanced stability or reduced taste issues in a solution), it could create a temporary market advantage or lead to the development of a "supergenerics" or authorized generics strategy by the innovator.

What Are the Regulatory Pathways for Cyclosporine Generics?

Generic cyclosporine products must demonstrate bioequivalence to the reference listed drug (RLD), which is typically the branded Sandimmune. This is achieved through Abbreviated New Drug Applications (ANDAs) submitted to regulatory agencies like the U.S. Food and Drug Administration (FDA).

Key aspects of the regulatory pathway include:

• Bioequivalence Studies: Generic manufacturers must conduct studies showing that their product performs comparably to the RLD in terms of rate and extent of absorption.
• ANDA Approval: The ANDA is approved if the generic drug is shown to be bioequivalent and meets all other quality and manufacturing standards.
• Patent Certifications: Generic applicants must certify the status of patents protecting the RLD. This involves Paragraph IV certifications, which can trigger patent litigation if the applicant asserts that the patents are invalid, unenforceable, or will not be infringed.

The Hatch-Waxman Act provides incentives for generic drug development, including market exclusivity for the first generic to successfully challenge a patent. However, the complex patent landscape for Sandimmune and its formulations has led to prolonged legal battles, influencing the timing of generic market entry and subsequent price competition.

How Will Biosimilar Competition Impact Cyclosporine's Future?

Cyclosporine is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, is not directly relevant to cyclosporine. The competition in the cyclosporine market comes from generic drugs, which are chemically identical to the branded product and manufactured by different companies.

The pathway for generic approval ensures that the active pharmaceutical ingredient is the same and that the drug performs identically in the body. The distinction is crucial:

• Generic Drugs: Identical active ingredient, chemically synthesized.
• Biosimilars: Highly similar to a biologic drug, but not identical, due to the complex manufacturing processes of biologics.

Therefore, the future market dynamics of cyclosporine will continue to be shaped by generic competition, patent challenges, and the introduction of improved formulations, rather than biosimilar entries.

Key Takeaways

• Expiring Core Patents: Foundational patents for cyclosporine have expired, enabling broad generic competition.
• Active Secondary Patent Landscape: Novartis and other innovators have secured secondary patents on formulations and indications, leading to ongoing litigation that can influence market exclusivity.
• Significant Price Erosion: Generic entry has drastically reduced the price of cyclosporine, with prices stabilizing at approximately 10-20% of the branded price.
• Fragmented Generic Market: Numerous manufacturers, including Teva, Sandoz, and Viatris, compete in the cyclosporine generics market.
• Modest Market Growth: The overall cyclosporine market is projected to grow modestly at 2-4% CAGR, driven by volume in transplant and autoimmune disease treatments, with generics dominating sales.
• Formulation-Specific Dynamics: Oral solutions and capsules have distinct market characteristics influenced by patient needs, manufacturing complexity, and patent strategies.
• Regulatory Pathway: Generic approval relies on ANDAs and bioequivalence studies, with patent certifications playing a crucial role in market entry timing.

Frequently Asked Questions

1. Are there any remaining patents that could prevent generic entry for Sandimmune?

While core composition of matter patents have expired, secondary patents related to specific improved formulations, manufacturing processes, or new indications could still be in effect or subject to ongoing litigation. These may influence the market entry of certain generic versions or specific formulations.

2. What is the typical lifespan of a generic drug's price depression after initial entry?

Price depression for a generic drug typically begins immediately upon first entry and continues for several years as more competitors emerge. Significant price erosion can occur within 1-3 years, with stabilization occurring over 5-7 years as the market matures and competition reaches a steady state.

3. How does the cost of Sandimmune oral solution compare to its capsule form, considering generics?

Generically, the oral solution may still be marginally more expensive per dose than capsules due to formulation complexities. However, the price difference has significantly narrowed, and the choice is often driven by patient need and physician preference rather than substantial cost disparity.

4. What is the regulatory status of bioequivalence for generic cyclosporine products?

All approved generic cyclosporine products must demonstrate bioequivalence to the reference listed drug (RLD) through FDA-approved studies. This ensures comparable safety and efficacy.

5. Can Novartis launch an "authorized generic" version of Sandimmune to compete with other generics?

Yes, Novartis, or its generics division Sandoz, can launch an authorized generic. This is a generic version of their own branded drug sold under a generic name, which can be a strategy to capture market share from independent generic manufacturers.

Citations

[1] U.S. Patent 4,115,709. (1977).